Recent price reductions to WHO-recommended TB tests and treatment should enable more countries to make these vital medical tools available

MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versions

MSF calls on Johnson & Johnson not to enforce its secondary patents on TB drug bedaquiline

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

The World Health Organization (WHO) announced global treatment guidance with new, safer and more effective six-month oral treatment regimen for multidrug-resistant tuberculosis.

The WHO recently released new rapid guidance recommending that children of all ages with drug-resistant tuberculosis (DR-TB) have access to all-oral treatment using the drugs bedaquiline and/or delamanid. However paediatric ...

Next week the Indian government is expected to decide whether it is willing to override patents on two critical tuberculosis (TB) drugs following a court petition filed at the Mumbai High Court by two survivors of TB and activists. MSF ...

The pharmaceutical corporation Johnson & Johnson (J&J) today announced a reduced price of US$1.50* per day for the tuberculosis (TB) drug bedaquiline, which is an important step that should allow more people with drug-resistant forms ...

MSF protested in front of the New York Stock Exchange in New York today, demanding the pharmaceutical corporation Johnson & Johnson make the tuberculosis drug bedaquiline available for all people with drug-resistant TB or no more than ...

Newer medicines for DR-TB are desperately needed, but barriers to access, including high prices, keep them out of reach for most people around the world.

Médecins Sans Frontières (MSF) launched a global campaign today calling on pharmaceutical corporation Johnson & Johnson (J&J) to lower the price of its anti-tuberculosis medicine bedaquiline to no more than US$1

MSF protests at J&J’s annual shareholders meeting to demand a say in how lifesaving tuberculosis drug developed with considerable joint efforts, including public funding and MSF operational research, will be made available and ...

Médecins Sans Frontières (MSF) is supporting a patent challenge filed in India this week by two tuberculosis survivors, to prevent pharmaceutical corporation Johnson & Johnson (J&J) from extending its monopoly on the tuberculosis drug ...

MSF welcomes new WHO treatment guidelines that recommend drug-resistant tuberculosis be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.

Groups pointed to the significant taxpayer money that J&J has received for the development and introduction of bedaquiline, and the need for these public investments to be reflected in the price of the drug.

We call on US pharma corporation Johnson & Johnson to cut key TB drug price in half

Urgent need to scale up newer tools available today to save lives; and develop a fast, safe and simple cure for TB.